Posicionamiento SEMERGEN en el abordaje de la insuficiencia cardíaca crónica en atención primaria

  1. M.J. Castillo Moraga 1
  2. M. Turégano-Yedro 2
  3. V. Pallarés-Carratalá 3
  4. M.C. Seoane-Vicente 4
  5. A. Serrano Cumplido 5
  6. A. Ruiz-García 6
  7. E. Martin-Rioobó 7
  8. C. Escobar-Cervantes 8
  9. J. Polo-García 9
  10. V. Barrios 10
  1. 1 Centro de Salud Sanlúcar Barrio Bajo, Sanlúcar de Barrameda, Cádiz, España
  2. 2 Centro de Salud Aldea Moret, Cáceres, España
  3. 3 Unidad de Vigilancia de la Salud, Unión de Mutuas, Castellón, España
  4. 4 Centro de Salud Acequión, Torrevieja, Alicante, España
  5. 5 Centro de Salud de Getxo, Bizkaia, España
  6. 6 Centro de Salud Universitario de Pinto, Pinto, Madrid, España
  7. 7 Instituto Maimónides de Investigación Biomédica de Córdoba IMIBIC Hospital Reina Sofía, Unidad de gestión clínica Poniente, Distrito sanitario Córdoba Guadalquivir, Córdoba, España
  8. 8 Servicio de Cardiología, Hospital Universitario La Paz, Madrid, España
  9. 9 Centro de Salud Casar de Cáceres, Cáceres, España
  10. 10 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España
Mostrar afiliaciones +
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Año de publicación: 2022

Número: 2

Páginas: 106-123

Tipo: Artículo

DOI: 10.1016/J.SEMERG.2021.10.007 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Semergen: revista española de medicina de familia

Objetivos de desarrollo sostenible

Resumen

La insuficiencia cardíaca (IC) es un problema de salud pública que genera una gran carga asistencial tanto hospitalaria como en atención primaria (AP). La publicación de numerosos estudios sobre IC durante los últimos años ha supuesto un cambio de paradigma en el abordaje de este síndrome, en el que la labor de los equipos de AP va adquiriendo un protagonismo mayor. Las recientes guías publicadas por la Sociedad Europea de Cardiología han introducido cambios fundamentalmente en el manejo del paciente con IC. La nueva estrategia propuesta, con fármacos que reducen las hospitalizaciones y frenen la progresión de la enfermedad, debe ser ya una prioridad para todos los profesionales implicados. En este documento de posicionamiento se analiza una propuesta de abordaje basada en equipos multidisciplinares con el liderazgo de los médicos de familia, clave para proporcionar una atención de calidad a lo largo de todo el proceso de la enfermedad, desde su prevención hasta el final de la vida

Referencias bibliográficas

  • S. Cinza-Sanjurjo, R.M. Micó-Pérez, S. Velilla-Zancada, M.A. Prieto-Díaz, G.C. Rodríguez-Roca, A. Barquilla García, et al. en representación de los investigadores del estudio IBERICAN Factores asociados al riesgo cardiovascular y enfermedad cardiovascular y renal en el estudio IBERICAN (Identificación de la poBlación Española de RIesgo CArdiovascular y reNal): resultados definitivos Semergen, 46 (2020), pp. 368-378 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Kahn, A.D. Grayson, P.S. Chaggar, M.J. Ng Kam Chuen, A. Scott, C. Hughes, et al. Primary care heart failure service identifies a missed cohort of heart failure patients with reduced ejection fraction Eur Heart J, 23 (2021), pp. 906-914 View Record in ScopusGoogle Scholar
  • A. Sicras-Mainar, A. Sicras-Navarro, B. Palacios, L. Varela, J.F. Delgado Epidemiology and treatment of heart failure in Spain: The HF-PATHWAYS study Rev Esp Cardiol (Engl Ed), S1885–5857 (2020), pp. 30521-30531 Google Scholar
  • J.U.G. Wagner, S. Dimmeler Cellular cross-talks in the dis- eased and aging heart J Mol Cell Cardiol, 138 (2020), pp. 136-146 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • T.A. McDonagh, M. Metra, M. Adamo, R.S. Gardner, A. Baumbach, M. Böhm, et al., ESC Scientific Document Group 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J, 42 (2021), pp. 3599-3726 View PDFCrossRefView Record in ScopusGoogle Scholar
  • I. Sayago-Silva, F. García-López, J. Segovia-Cubero Epidemiología de la insuficiencia cardiaca en España en los últimos 20 años Rev Esp Cardiol, 66 (2013), pp. 649-656 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.F. Delgado, J. Oliva, M. Llano, D. Pascual-Figal, J.J. Grillo, J. Comín-Colet, et al. Costes sanitarios y no sanitarios de personas que padecen insuficiencia cardiaca crónica sintomática en España Rev Esp Cardiol, 67 (2014), pp. 643-650 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • C. Escobar, L. Varela, B. Palacios, M. Capel, A. Sicras, A. Sicras, et al. Costs and healthcare utilisation of patients with heart failure in Spain BMC Health Serv Res, 20 (2020), p. 964 View Record in ScopusGoogle Scholar
  • A. Groenewegen, F.H. Rutten, M. Mosterd, A.W. Hoes Epidemiology of heart failure Eur J Heart Fail, 22 (2020), pp. 1342-1356 View PDFCrossRefView Record in ScopusGoogle Scholar
  • P.M. Seferovic, P. Vardas, E.A. Jankowska, A.P. Maggioni, A.M. Timmis, I. Milinkovic, et al. The heart failure association atlas: Heart failure epidemiology and management statistics 2019 Eur J Heart Fail, 23 (2021), pp. 906-914 View PDFCrossRefView Record in ScopusGoogle Scholar
  • B. Bozkurt, A.J. Coats, H. Tsutsui, M. Abdelhamid, S. Adamopoulos, N. Albert, et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Eur J Card Fail, 23 (2021), pp. 352-380 View PDFCrossRefView Record in ScopusGoogle Scholar
  • C.W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D.E. Casey Jr., M.M. Colvin, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Circulation, 136 (2017), pp. e137-e161 View PDFCrossRefView Record in ScopusGoogle Scholar
  • J. Mant, J. Doust, A. Roalfe, P. Barton, M.R. Cowie, P. Glasziou, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care Health Technol Assess, 13 (2009), pp. 1-207 View Record in ScopusGoogle Scholar
  • The Criteria Committee of the New York Heart Association Nomenclature and criteria for diagnosis of diseases of the heart and great vessels (9th ed), Little & Brown, Boston, Mass (1994) Google Scholar
  • A.K. Roalfe, C.J. Taylor, J.C. Kelder, A.W. Hoes, F.D.R. Hobbs Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies ESC Heart Fail, 8 (2021), pp. 2193-2201 View PDFCrossRefView Record in ScopusGoogle Scholar
  • E.M. Boorsma, J.M. Ter Maaten, K. Damman, W. Dinh, F. Gustafsson, S. Goldsmith, et al. Congestion in heart failure: A contemporary look at physiology, diagnosis and treatment Nat Rev Cardiol, 17 (2020), pp. 641-655 View PDFCrossRefView Record in ScopusGoogle Scholar
  • V. Barrios, C. Escobar, A. de La Sierra, J.L. Llisterri, D. González-Segura Detection of unrecognized clinical heart failure in elderly hypertensive women attended in primary care setting Blood Press, 19 (2010), pp. 301-307 View PDFCrossRefView Record in ScopusGoogle Scholar
  • A. Tymińska, K. Ozierański, P. Balsam, A. Kapłon-Cieślicka, C. Maciejewski, M. Marchel, et al. The prevalence and association of major ECG abnormalities with clinical characteristics and the outcomes of real-life heart failure patients-Heart Failure Registries of the ESC Kardiol Pol, 79 (2021), pp. 980-987 View PDFCrossRefView Record in ScopusGoogle Scholar
  • J.A. Cannon, L. Shen, P.S. Jhund, I.S. Anand, M. Komakda, R.S. McKelvie, et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial Eur J Heart Fail, 18 (2016), pp. 1021-1031 View PDFCrossRefView Record in ScopusGoogle Scholar
  • T.A. Buchan, C. Ching, F. Foroutan, A. Malik, J.F. Daza, N.N.F. Hing, et al. Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis Heart Fail Rev (2021) Online ahead of print. https://doi.org/10.1007/s10741-021-10136-3 Google Scholar
  • J.C. Kelder, M.J. Cramer, W.M. Verweij, D.E. Grobbee, A.W. Hoes Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure J Card Fail, 17 (2011), pp. 729-734 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M.K. Davies, C.R.C.R. Gibbs, G.Y.H. Lip ABC of heart failure investigation BMJ, 320 (2000), pp. 297-300 Google Scholar
  • J.M. Verdú, J. Comín-Colet, M. Domingo, J. Lupón, M. Gómez, L. Molina, et al. Punto de corte óptimo de NT-proBNP para el diagnóstico de insuficiencia cardiaca mediante un test de determinación rápida en atención primaria Rev Esp Cardiol, 65 (2012), pp. 613-619 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • N.E. Ibrahim, J.C. Burnett Jr., J. Butler, A. Camacho, G.M. Felker, M. Fiuzat, et al. Natriuretic peptides as inclusion criteria in clinical trials: a JACC: Heart failure position paper JACC Heart Fail, 8 (2020), pp. 347-358 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • D.K. Gupta, T.J. Wang Natriuretic peptides and cardiometabolic health Circ J, 79 (2015), pp. 1647-1655 Google Scholar
  • V. Barrios, C. Escobar, C. Ortíz, J. Cosín, D.A. Pascual, X. García-Moll, et al. Manejo de los pacientes con insuficiencia cardiaca atendidos en la consulta de cardiología: Estudio IC-BERG Rev Clin Esp, 220 (2020), pp. 339-349 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Vaduganathan, B.L. Claggett, P.S. Jhund, J.W. Cunningham, J. Pedro Ferreira, F. Zannad, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials Lancet, 396 (2020), pp. 121-128 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. McDonald, S. Virani, M. Chan, A. Ducharme, J.A. Ezekowitz, N. Giannetti, et al. CCS/CHFS heart failure guidelines update: Defining a new pharmacologic standard of care for heart failure with reduced ejection fraction Can J Cardiol, 37 (2021), pp. 531-546 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • T.M. Maddox, J.L. Januzzi Jr., L.A. Allen, K. Breathett, J. Butler, L.L. Davis, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee J Am Coll Cardiol, 77 (2021), pp. 772-810 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.J. McMurray, M. Packer, A.S. Desai, G. Gong, M.P. Lefkowitz, A.R. Rizkala, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med, 371 (2014), pp. 993-1004 View PDFCrossRefGoogle Scholar
  • E.J. Velazquez, D.A. Morrow, A.D. deVore, C.I. Duffy, A.P. Ambrosy, K. McCague, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure N Engl J Med, 380 (2019), pp. 539-548 View PDFCrossRefView Record in ScopusGoogle Scholar
  • J.L. Januzzi Jr., M.F. Prescott, J. Butler, G.M. Felker, A.S. Maisel, K. McCague, et al. Association of change in N-terminal pro- B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction JAMA, 315 (2019), pp. 1-11 View Record in ScopusGoogle Scholar
  • K. Damman, M. Gori, B. Claggett, P.S. Jhund, M. Senni, M.P. Lefkowitz, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure JACC Heart Fail, 6 (2018), pp. 489-498 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • O. Vardeny, B. Claggett, J. Kachadourian, A.S. Desai, M. Packer, J. Rouleau, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: The PARADIGM-HF trial Eur J Heart Fail, 21 (2019), pp. 337-341 View PDFCrossRefView Record in ScopusGoogle Scholar
  • R. Garg, S. Yusuf Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart fail Collaborative Group on ACE Inhibitor Trials JAMA, 273 (1995), pp. 1450-1456 View PDFCrossRefView Record in ScopusGoogle Scholar
  • SOLVD. Investigators, S. Yusuf, B. Pitt, C.E. Davis, W.B. Hood, J.N. Cohn Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med, 325 (1991), pp. 293-302 Google Scholar
  • M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, E.M. Gilbert, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure U.S. Carvedilol Heart Failure Study Group N Engl J Med, 334 (1996), pp. 1349-1355 View Record in ScopusGoogle Scholar
  • A. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, J. Kjekshus, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) MERIT-HF Study Group JAMA, 283 (2000), pp. 1295-1302 Google Scholar
  • M. Packer, M.B. Fowler, E.B. Roecker, A.J. Coats, H.A. Katus, H. Krum, et al., Carvedilol prospective randomized cumulative survival study group Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study Circulation, 106 (2002), pp. 2194-2199 View Record in ScopusGoogle Scholar
  • M.D. Flather, M.C. Shibata, A.J. Coats, D.J. Van Veldhuisen, A. Parkhomenko, J. Borbola, et al., SENIORS Investigators Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J, 26 (2005), pp. 215-225 View PDFCrossRefView Record in ScopusGoogle Scholar
  • CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial Lancet, 353 (1999), pp. 9-13 Google Scholar
  • B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, et al., Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N. Engl J Med, 341 (1999), pp. 709-717 View Record in ScopusGoogle Scholar
  • F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, et al., EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med, 364 (2011), pp. 11-21 View PDFCrossRefView Record in ScopusGoogle Scholar
  • B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med, 373 (2015), pp. 2117-2128 View Record in ScopusGoogle Scholar
  • B. Neal, V. Perkovic, K.W. Mahaffey, D. de Zeeuw, G. Fulcher, N. Erondu, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med, 377 (2017), pp. 644-657 View Record in ScopusGoogle Scholar
  • S.D. Wiviott, I. Raz, M.P. Bonaca, O. Mosenzon, E.T. Kato, A. Cahn, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med, 380 (2019), pp. 347-357 View PDFCrossRefView Record in ScopusGoogle Scholar
  • T.A. Zelniker, S.D. Wiviott, I. Raz, K. Im, E.L. Goodrich, M.P. Bonaca, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials Lancet, 393 (2019), pp. 31-39 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.J.V. McMurray, S.D. Solomon, S.E. Inzucchi, L. Køber, M.N. Kosiborod, F.A. Martinez, et al. DAPA-HF Trial Committees and Investigators Dapagliflozin in patients with heart failure and reduced ejection fraction N Engl J Med, 381 (2019), pp. 1995-2008 View PDFCrossRefView Record in ScopusGoogle Scholar
  • M. Packer, S.D. Anker, J. Butler, G. Filippatos, S.J. Pocock, P. Carson, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure N Engl J Med, 383 (2020), pp. 1413-1424 View PDFCrossRefView Record in ScopusGoogle Scholar
  • F. Zannad, J.P. Ferreira, S.J. Pocock, S.D. Anker, J. Butler, G. Filippatos, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials Lancet, 396 (2020), pp. 819-829 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • L.H. Lund, B. Claggett, J. Liu, C.S. Lam, P.S. Jhund, G.M. Rosano, et al. Heart failure with mid- range ejection fraction in CHARM: Characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum Eur J Heart Fail, 20 (2018), pp. 1230-1239 View PDFCrossRefView Record in ScopusGoogle Scholar
  • S.D. Solomon, B. Claggett, E.F. Lewis, A. Desai, I. Anand, N.K. Sweitzer, et al. TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction Eur Heart J, 37 (2016), pp. 455-462 View PDFCrossRefView Record in ScopusGoogle Scholar
  • S.D. Solomon, J.J.V. McMurray, I.S. Anand, J. Ge, C.S.P. Lam, A.P. Maggioni, et al. PARAGON-HF Investigators and Committees Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction N Engl J Med, 381 (2019), pp. 1609-1620 View PDFCrossRefView Record in ScopusGoogle Scholar
  • B.A. Borlaug Evaluation and management of heart failure with preserved ejection fraction Nat Rev Cardiol, 17 (2020), pp. 559-573 View PDFCrossRefView Record in ScopusGoogle Scholar
  • J.E. Ho, M.M. Redfield, G.D. Lewis, W.J. Paulus, C.S.P. Lam Deliberating the diagnostic dilemma of heart failure with preserved ejection fraction Circulation, 142 (2020), pp. 1770-1780 View PDFCrossRefView Record in ScopusGoogle Scholar
  • T.M. Gorter, D.J. van Veldhuisen, J. Bauersachs, B.A. Borlaug, J. Celutkiene, A.J.S. Coats, et al. Right heart dysfunction and failure in heart failure with preserved ejection fraction: Mechanisms and management position statement on behalf of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, 20 (2018), pp. 16-37 View PDFCrossRefView Record in ScopusGoogle Scholar
  • J.G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, J. Taylor PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur Heart J, 27 (2006), pp. 2338-2345 View PDFCrossRefView Record in ScopusGoogle Scholar
  • B.M. Massie, P.E. Carson, J.J. McMurray, M. Komajda, R. McKelvie, M.R. Zile, et al. Irbesartan in patients with heart failure and preserved ejection fraction N Engl J Med, 359 (2008), pp. 2456-2467 View PDFCrossRefView Record in ScopusGoogle Scholar
  • S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, et al. CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial Lancet, 362 (2003), pp. 777-781 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • D.J. Van Veldhuisen, A. Cohen-Solal, M. Böhm, S.D. Anker, D. Babalis, M. Roughton, et al. SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) J Am Coll Cardiol, 53 (2009), pp. 2150-2158 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • B. Pitt, M.A. Pfeffer, S.F. Assmann, R. Boineau, I.S. Anand, B. Claggett, et al. TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction N Engl J Med, 370 (2014), pp. 1383-1392 View PDFCrossRefView Record in ScopusGoogle Scholar
  • S.D. Anker, J. Butler, G. Filippatos, J.P. Ferreira, E. Bocchi, M. Böhm, et al. EMPEROR-preserved trial investigators empagliflozin in heart failure with a preserved ejection fraction N Engl J Med, 385 (2021), pp. 1451-1461 View PDFCrossRefView Record in ScopusGoogle Scholar
  • M.G. Del Buono, G. Iannaccone, R. Scacciavillani, S. Carbone, M. Camilli, G. Niccoli, et al. Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence Prog Cardiovasc Dis, 63 (2020), pp. 570-584 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • T.J. Fendler, K.M. Swetz, L.A. Allen Team-based palliative and end-of-life care for heart failure Heart Fail Clin, 11 (2015), pp. 479-498 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • E.D. Adler, J.Z. Goldfinger, J. Kalman, M.E. Park, D.E. Meier Palliative care in the treatment of advanced heart failure Circulation, 120 (2009), pp. 2597-2606 View Record in ScopusGoogle Scholar
  • J. Maciver, H.J. Ross A palliative approach for heart failure end-of-life care Curr Opin Cardiol, 33 (2018), pp. 202-207 View PDFCrossRefView Record in ScopusGoogle Scholar
  • M. Fralick, M. Colacci, D. Thiruchelvam, T. Gomes, D.A. Redelmeier Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus Diabetes Obes Metab, 23 (2021), pp. 950-960 View PDFCrossRefView Record in ScopusGoogle Scholar
  • N.R. Jones, F.D.R. Hobbs, C.J. Taylor Prognosis following a diagnosis of heart failure and the role of primary care: A review of the literature BJGP Open, 1 (2017) bjgpopen17X101013 Google Scholar
  • C. Escobar, L. Varela, B. Palacios, M. Capel, A. Sicras-Mainar, A. Sicras-Navarro, et al. Características clínicas, manejo y riesgo de complicaciones a un año en pacientes con insuficiencia cardíaca con y sin diabetes tipo 2 en España Rev Clin Esp (2021), 10.1016/j.rce.2021.04.008 View PDFGoogle Scholar
  • A. Takeda, N. Martin, R.S. Taylor, S.J. Taylor Disease management interventions for heart failure Cochrane Database Syst Rev, 1 (2019), p. CD002752 View Record in ScopusGoogle Scholar
  • V. Pallarés-Carratalá, C. Górriz-Zambrano, J.L. Llisterri-Caro, J.L. Górriz La pandemia de COVID-19: una oportunidad para cambiar la forma en que cuidamos a nuestros pacientes Semergen, 46 (S1) (2020), pp. 3-5 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • V. Barrios, J. Cosín-Sales, M. Bravo, C. Escobar, J.M. Gámez, A. Huelmos, et al. La consulta telemática para el cardiólogo clínico en tiempos de la COVID-19: Presente y futuro. Documento de consenso de la Sociedad Española de Cardiología Rev Esp Cardiol, 73 (2020), pp. 910-918 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Anguita, A. Bayés-Genís, J.M. Cepeda, S. Cinza, J. Cosín, M. Crespo Leiro, et al. Consenso de expertos sobre la insuficiencia cardiaca con fracción de eyección reducida: más allá de las guías Rev Esp Cardiol, 20 (Supl B) (2020), pp. S1-S46 Google Scholar
Fuente de los datos: Dialnet